Suche
  • ODI Pharma

ODI Pharma achieves milestone towards market entry in Poland

ODI Pharma AB (“ODI” or the “Company”) announces that its subsidiary ODI Pharma Polska Sp. z o.o. has finalized documentation and filed the application to obtain a marketing authorization for the sale of medicinal cannabis, manufactured by Aphria Inc., with the Polish Health Agency.


In order for companies to sell and market medical and pharmaceutical cannabis products in Poland, companies, as well as their suppliers and distributors are required to have a set of permits and certifications. ODI Pharma and its strategic partners have been working excessively to ensure that documentation complies with the Polish government regulations regarding relevant certifications and permits, and that the patients are able to access safe products with high quality.

In November 2020, the Company announced that it had streamlined its supply chain and executed a supply agreement with Aphria Inc.’s wholly owned German subsidiary, CC Pharma GmbH (“CC Pharma”) with the aim of securing regulatory approval for import and sale of the co-branded products in Poland. Together with CC Pharma, the Company has now finalized documentation and filed the application to obtain a marketing authorization with the Polish Health Agency responsible to give permission to operate in the pharmaceutical industry in Poland.


CEO Derek Simmross comments:

“Firstly, we would like to thank CC Pharma for the efficient collaboration in documentation. All documentation has been updated and was received by the Polish Health Agency on 22 Feb 2021. The supply agreement with CC Pharma makes us confident that efficiencies will lead to a very smooth process in the future. Secondly, we see that there is a lot of demand in Poland which we are looking forward to be in a position to fulfill. We are excitedly looking forward to complete the process in the not-so-distant future with timing dependent on the input of the Polish authorities.”


For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB

E-mail: info@odipharma.com

This release contains information that ODI Pharma is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on 22 February 2021.



ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. ODI will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.

0 Kommentare

Aktuelle Beiträge

Alle ansehen

ODI Pharma proceeds with its plans and launches Project Skin

ODI Pharma AB (“ODI” or “the Company”) announces that the Board of Directors has decided to expand ODI’s current business with specialized, highly CBD-infused skin care products (“Project Skin”). The

ODI PHARMA AB AND APHRIA INC. EXECUTE SUPPLY AGREEMENT

Stockholm, Sweden and Leamington, Ontario – November 2nd, 2020 – ODI Pharma AB (“ODI”, ISIN SE0013409760) today announced that, despite COVID 19 delays, it has streamlined its supply chain and execute

Original on Transparent.png